BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14529399)

  • 1. Dual COX inhibition and upper gastrointestinal damage.
    Skelly MM; Hawkey CJ
    Curr Pharm Des; 2003; 9(27):2191-5. PubMed ID: 14529399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract.
    Lanas A; Panés J; Piqué JM
    Curr Pharm Des; 2003; 9(27):2253-66. PubMed ID: 14529405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
    Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
    Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
    Lehmann FS; Beglinger C
    Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
    Perini R; Fiorucci S; Wallace JL
    Can J Gastroenterol; 2004 Apr; 18(4):229-36. PubMed ID: 15054499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs.
    Whittle BJ
    Fundam Clin Pharmacol; 2003 Jun; 17(3):301-13. PubMed ID: 12803569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
    Feldman M; McMahon AT
    Ann Intern Med; 2000 Jan; 132(2):134-43. PubMed ID: 10644275
    [No Abstract]   [Full Text] [Related]  

  • 12. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibition versus gastroprotection with dual COX inhibitors: an evidence-based approach.
    Thompson AJ; Yeomans ND
    Curr Pharm Des; 2003; 9(27):2221-8. PubMed ID: 14529403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs.
    Whittle BJ
    Curr Opin Pharmacol; 2004 Dec; 4(6):538-45. PubMed ID: 15525540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.
    Chan FK
    Curr Pharm Des; 2003; 9(27):2213-9. PubMed ID: 14529402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal safety of selective COX-2 inhibitors.
    Hawkey CJ; Skelly MM
    Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs.
    Bjarnason I; Scarpignato C; Holmgren E; Olszewski M; Rainsford KD; Lanas A
    Gastroenterology; 2018 Feb; 154(3):500-514. PubMed ID: 29221664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
    Jiménez P; García A; Santander S; Piazuelo E
    Curr Pharm Des; 2007; 13(22):2261-73. PubMed ID: 17691999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.